Why What You May Not Know About Fecal Immunochemical Testing MattersWhy What You May Not Know About Fecal Immunochemical Testing Matters
A partir d'une revue systématique de la littérature publiée jusqu'en octobre 2018 (31 études, 120 255 participants), cette méta-analyse évalue, en fonction des seuils de positivité et du nombre de fois que le test est réalisé, la sensibilité, la spécificité et les rapports de vraisemblance de tests immunochimiques de recherche de sang occulte dans les selles pour détecter un adénome colorectal de stade avancé ou une lésion cancéreuse chez les personnes présentant un risque intermédiaire de développer un cancer colorectal
Some U.S. primary care physicians and many of their patients may be unaware that fecal immunochemical tests (FITs) are noninvasive, easy to prepare, and inexpensive and have effectiveness similar to that of colonoscopy when used in a consistent, programmatic fashion to screen for colorectal cancer (CRC) (1). The paucity of studies comparing FITs and colonoscopy in 2000 may have been why Podolsky advocated for insurers to cover colonoscopic screening in all average-risk persons aged 50 years or older (2). Shortly thereafter, Congress ordered Medicare to cover the procedure without requiring published evidence of its superiority over less invasive and cheaper tests. In 2019, although trials are under way, we still lack published results of randomized controlled trials showing that colonoscopy is superior to FITs.
Annals of Internal Medicine , article en libre accès, 2018